Your browser doesn't support javascript.
loading
Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Marcos-Jiménez, Ana; Carvoeiro, Daniela Claudino; Ruef, Nora; Cuesta-Mateos, Carlos; Roy-Vallejo, Emilia; Gómez-García de Soria, Valle; Laganá, Claudio; Del Campo, Lourdes; Zubiaur, Pablo; Villapalos-García, Gonzalo; Abad-Santos, Francisco; Stein, Jens V; Muñoz-Calleja, Cecilia.
Afiliación
  • Marcos-Jiménez A; Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland.
  • Carvoeiro DC; Department of Immunology, Biomedical Research Institute La Princesa Hospital (IIS-IP), Madrid, Spain.
  • Ruef N; Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland.
  • Cuesta-Mateos C; Department of Oncology, Microbiology and Immunology, University of Fribourg, Fribourg, Switzerland.
  • Roy-Vallejo E; Department of Immunology, Biomedical Research Institute La Princesa Hospital (IIS-IP), Madrid, Spain.
  • Gómez-García de Soria V; Department of Internal Medicine, IIS-IP, Madrid, Spain.
  • Laganá C; Department of Hematology, IIS-IP, Madrid, Spain.
  • Del Campo L; Department of Radiology, IIS-IP, Madrid, Spain.
  • Zubiaur P; Department of Radiology, IIS-IP, Madrid, Spain.
  • Villapalos-García G; Department of Medicine, School of Medicine, Universidad Autónoma of Madrid, Madrid, Spain.
  • Abad-Santos F; Department of Clinical Pharmacology, University Hospital La Princesa, Teófilo Hernando Institute, Universidad Autónoma de Madrid, IIS-IP, Madrid, Spain.
  • Stein JV; Center for Biomedical Research Network on Liver and Digestive Diseases (CIBERehd), Health Research Institute Carlos III, Madrid, Spain.
  • Muñoz-Calleja C; Department of Clinical Pharmacology, University Hospital La Princesa, Teófilo Hernando Institute, Universidad Autónoma de Madrid, IIS-IP, Madrid, Spain.
Blood Adv ; 7(11): 2418-2430, 2023 06 13.
Article en En | MEDLINE | ID: mdl-36583674
The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome-positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib uptake. To date, the underlying physiological process linking dasatinib to lymphocytosis remains unknown. Here, we used a small rodent model to examine the mechanism of dasatinib-induced lymphocytosis, focusing on lymphocyte trafficking into and out of secondary lymphoid organs. Our data indicate that lymphocyte homing to lymph nodes and spleen remained unaffected by dasatinib treatment. In contrast, dasatinib promoted lymphocyte egress from spleen with kinetics consistent with the observed lymphocytosis. Unexpectedly, dasatinib-induced lymphocyte egress occurred independently of canonical sphingosine-1-phosphate-mediated egress signals; instead, dasatinib treatment led to a decrease in spleen size, concomitant with increased splenic stromal cell contractility, as measured by myosin light chain phosphorylation. Accordingly, dasatinib-induced lymphocytosis was partially reversed by pharmacological inhibition of the contraction-promoting factor Rho-rho associated kinase. Finally, we uncovered a decrease in spleen size in patients with CML who showed lymphocytosis immediately after dasatinib treatment, and this reduction was proportional to the magnitude of lymphocytosis and dasatinib plasma levels. In summary, our work provides evidence that dasatinib-induced lymphocytosis is a consequence of drug-induced contractility of splenic stromal cells.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Linfocitosis Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Linfocitosis Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos